Oxford Instruments Hits £500m Revenue, Sells Quantum Unit & Launches £50m Buyback

A Triple Whammy: Oxford Instruments Smashes Records While Reshaping Its Future

Well, Oxford Instruments isn’t just tinkering around the edges. Their latest full-year results aren’t just good – they’re a statement of intent, wrapped in a £500 million revenue milestone and tied with a bow of strategic boldness. Hitting half a billion in revenue for the first time? Tick. Selling off their quantum business (NanoScience) for £60 million? Tick. Launching a chunky £50 million share buyback? Big, fat tick. Let’s dissect why this matters.

The Headline Numbers: More Than Just a Pretty Figure

Crossing the £500m revenue threshold (specifically £500.6m, up 6.5% on an organic constant currency basis) is symbolic, but the underlying performance is what truly impresses:

• Profit Power: Adjusted operating profit jumped 10.8% (OCC) to £82.2m. Crucially, the adjusted operating profit margin expanded by 70 basis points to 17.8% (OCC), showing they’re not just growing, they’re growing smarter and more profitably.
• Cash is King (and Queen): Net cash ended strong at £84.4m, even after £15.4m spent on acquisitions. Normalised cash conversion leapt to a healthy 89% from 64% last year – a sign of efficient operations.
• Dividend Delight: Shareholders get a 6.7% dividend hike to 22.2p per share. Rewarding loyalty while executing strategy? That’s a balancing act done well.

Where the Growth Came From

It wasn’t uniform, but the engines fired where it counted:

• Semiconductor & Materials Analysis: These segments were the stars, driving growth. Demand for tools supporting compound semiconductors (think AI chips, data centres) and materials analysis (from EV batteries to solar energy) was robust.
• Commercial Pivot Pays Off: Revenue from commercial customers now makes up ~50% of the total and grew at double-digit rates. This shift away from over-reliance on academia is a key strategic win.
• Regional Rebalancing: Strong performances in North America, Asia (ex-China), and Europe offset the deliberate, and now completed, pivot away from sensitive quantum/semiconductor sales in China. Growth is coming from the right places.
• Offsetting Weakness: The healthcare & life science sector remained a drag, particularly impacting the Belfast imaging business. However, its weakness was more than covered by the strength elsewhere.

The Big Strategic Play: Selling NanoScience

This isn’t just a sale; it’s a sharp strategic recalibration. Selling the NanoScience quantum business to Quantum Design for £60m (with £3m deferred) signals a clear focus:

• Sharpening the Focus: CEO Richard Tyson explicitly stated this allows Oxford to concentrate capital and effort on businesses with “strong growth and margin characteristics.” Quantum, while fascinating tech, likely had a less certain commercial trajectory and lower margins than their core segments.
• Margin Acceleration: The sale directly accelerates progress towards the group’s medium-term target of 20%+ adjusted operating margins. NanoScience, even after its return to profitability this year, operated in the lower-margin Advanced Technologies division.
• Cleaning the Slate: It simplifies the group structure further, following the previous reorganisation into the two core divisions (Imaging & Analysis and Advanced Technologies).

One-off costs of £2m-£3m are expected, but the strategic clarity and financial benefit are compelling. Kudos for turning the business around and then crystallising its value efficiently.

Rewarding Shareholders: The £50m Buyback

This is where the strong balance sheet (£84.4m net cash) and the NanoScience proceeds come together brilliantly. The launch of a £50m share buyback programme sends powerful signals:

• Confidence: Management clearly believes the shares are undervalued. Returning this capital directly to shareholders is a strong vote of confidence in the future.
• Efficient Capital Allocation: With the core business performing well, strategic acquisitions likely targeted in Imaging & Analysis, and the dividend covered, a buyback is an efficient way to return surplus capital.
• Enhancing Returns: Reducing the share count should boost earnings per share (EPS) for remaining shareholders.

It’s a tangible demonstration of delivering on the promise to “create value for shareholders.”

Divisional Deep Dive: Two Engines Firing

1. Imaging & Analysis (66% Revenue, 93% Group Profit)

The powerhouse. Revenue £330.5m (up slightly OCC), but the margin story shines: OCC adjusted operating margin hit 24.7% (up 60bps), hitting the top end of medium-term guidance. Key drivers:

• Operational Excellence: Integrating five business units under one leader delivered £1.9m cost efficiencies and synergies.
• Market Wins: Semiconductor revenue surged 35% CC; Materials Analysis orders up 8% CC. Raman and EBSD products were standouts.
• Acquisition Integration: WITec (Raman) and FemtoTools (nanoindentation) performing well, launching products under the Oxford brand.
• Challenges: Healthcare & Life Science weakness persisted, holding back overall growth. Product line rationalisation is underway in Belfast to address low-margin drags.

2. Advanced Technologies (34% Revenue, 7% Group Profit)

A year of transformation. Revenue soared 21.3% CC to £170.1m. Crucially, the adjusted operating margin rocketed 360bps CC to 4.5%.

• Compound Semi Shines: The new Severn Beach facility is delivering, with revenue & orders up 13% CC. Focus on high-margin niches (GaN for power/data centres) is working.
• Quantum Exit: NanoScience was returned to profit before the sale, shipping key systems (like the large Proteox QX). The sale removes this segment going forward.
• Operational Fix: Supply chain and inventory issues tackled, leading to a record final quarter for shipments.

Outlook: Focused & Confident (Despite the Noise)

CEO Richard Tyson acknowledges macro uncertainty but oozes confidence. Why?

• Strong Orderbook: Provides good visibility (~5 months cover for I&A, ~9 months for AT excl. lumpy quantum).
• Strategic Momentum: Benefits from simplification, operational transformation (lean manufacturing roll-out), and commercial focus are still flowing through.
• Tariff Mitigation: Actively engaging with customers; key semiconductor lines currently exempt from US tariffs.
• Market Positioning: Structural growth drivers in materials analysis, semiconductors, and healthcare/life science remain compelling long-term.
• Financial Flexibility: Strong balance sheet post-NanoScience sale and buyback leaves room for continued R&D investment (8.2% of revenue) and targeted M&A in I&A.

The medium-term targets (5-8% organic revenue growth, 20%+ adjusted op margin, >85% cash conversion) look firmly within reach, especially with the quantum business sold.

The Bottom Line: A Company Hitting Its Stride

Oxford Instruments’ results are a masterclass in strategic execution. Hitting £500m revenue is a milestone, but the real story is how they did it: driving profitable growth in core markets, successfully pivoting regions and customer focus, fixing underperforming units, and making tough but value-enhancing portfolio decisions (NanoScience sale).

The £50m buyback isn’t just a sweetener; it’s a declaration that the streamlined, higher-margin Oxford Instruments is confident in its future and committed to shareholder returns. They’ve navigated headwinds (China pivot, life science slump), controlled costs, improved cash flow, and emerged leaner and more focused.

For investors, this paints a picture of a company maturing strategically, delivering on its promises, and positioning itself for sustainable, higher-quality growth. The sale of NanoScience removes uncertainty and sharpens the investment case squarely on their high-margin, structurally growing core. One to watch? Absolutely. One executing with conviction? Undoubtedly.